

Prostatype Genomics' CEO updates on the company's commercial potential in USA in a filmed presentation

Prostatype Genomics AB announces that a filmed CEO presentation and Q&A session with an analyst from Redeye has just been published. The company's commercial potential in the U.S. was in focus, and here the company is in the final phase of the process to achieve a crucial milestone: approval for reimbursement by Medicare.

During the presentation, Fredrik Rickman clarifies that the Medicare process is ongoing and that the company is awaiting the next feedback, potentially an approval, but that it is Medicare alone that controls the timing. Furthermore, it is explained that the company is commercially and regulatorily very well prepared, and that Prostatype® is already in clinical use in USA, which means that the company can quickly translate clinical use into actual revenues.

The filmed presentation and Q&A session can be accessed via the following link: <https://www.redeye.se/video/event-presentation/1089660/prostatype-genomics-ceo-fredrik-rickman-presents-at-redeye-theme-event-commercialization-in-life-science-march-20-2025>

For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

About Prostatype Genomics AB

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.